Direct-to-consumer prescription drug advertising faces renewed regulatory scrutiny after the Advertising Standards Authority found a Wellington billboard for Novo Nordisk Pharmaceuticals weight loss drug Wegovy failed to display mandatory risk information in a readable font size. According to the advertising watchdog, the 30-second digital rotation ad featured critical safety details in text that was too small for consumers to reasonably read and understand.
Wegovy Billboard Prompts Regulatory Review in Wellington
The Advertising Standards Authority investigated a formal complaint regarding the Wegovy digital billboard displayed in Wellington. In response to the finding, advertiser Novo Nordisk Pharmaceuticals agreed to alter both the font size and layout for future campaigns, effectively settling the matter.
Dr Janet Joek, a professor of public health at the University of Otago, stated that consumers need clear, balanced, and well-explained information regarding the risks, side effects, and potential benefits of medications before consulting a physician. Hoek argued that a 30-second advertisement featuring key details in small or scrolling print fails to deliver that necessary standard of information.
Pro Tip: Understanding Prescription Drug Claims
Global Policy Comparisons: New Zealand and the US
The case has reignited a broader debate over whether pharmaceutical companies should be permitted to market prescription drugs directly to the public. According to associate professor of psychological medicine David Menkes at the University of Auckland, New Zealand and the United States remain the only high-income countries allowing direct-to-consumer prescription drug advertising.
“This New Zealand policy, just like the one in the US, has done more harm than good and should be ditched as soon as there’s political will to do so,” Menkes told Checkpoint. Menkes added that decades of research show direct-to-consumer advertising frequently contributes to over-diagnosis and over-treatment, although determining the exact net public health effect remains complex.
Conversely, Medicines New Zealand, an industry representative body, defends the practice. Chief Executive Dr Graeme Jarvis stated that member companies follow rigorous internal processes to ensure promotional claims are accurate, substantiated by references, and compliant with local legislation and regulations.
“Whilst in this case the compliance checks that will undoubtedly have been undertaken by the advertiser in advance of the billboard going up, may not have been 100 percent full proof, overall, this case demonstrates the system of self-regulation and checks and balances works to ensure that expected standards are met for public advertising,” Jarvis said. He noted that the Ministry of Health previously conducted two independent reviews finding no evidence to justify a total ban.
Medical Council Concerns Versus Industry Standards
Opposition to direct marketing extends beyond academic circles. The Council of Medical Colleges does not support the practice, warning that direct-to-consumer advertising can drive up healthcare costs, prompt inappropriate prescribing, cause overtreatment, and risk damaging the doctor-patient relationship.
Jarvis countered that banning the practice in New Zealand would backfire by driving patients toward unregulated digital sources. He argued that a ban would leave the public “at the mercy of seeking or obtaining unregulated, unbalanced, and harmful information from overseas sources and illicit domestic purveyors of prescription medicines using the internet.”
Did You Know?
New Zealand and the United States are unique among high-income nations in permitting broad direct-to-consumer advertising for prescription medications, a regulatory framework supported by industry groups but opposed by major medical associations.
Frequently Asked Questions
Are prescription drugs advertised directly to consumers everywhere?
No. New Zealand and the United States are the only high-income countries that permit pharmaceutical companies to advertise prescription medications directly to the general public.
What did the Advertising Standards Authority rule regarding the Wegovy billboard?
The authority found that mandatory information displayed on a digital billboard in Wellington was not sufficiently accessible to be read and understood by consumers. The advertiser, Novo Nordisk Pharmaceuticals, agreed to modify font sizes and layouts for future campaigns.
What are the primary arguments against direct-to-consumer drug ads?
According to the Council of Medical Colleges and participating academics, such advertising can increase costs, encourage inappropriate prescribing, lead to over-diagnosis, and strain the doctor-patient relationship.
How does the pharmaceutical industry defend these advertisements?
Medicines New Zealand maintains that companies adhere to rigorous internal compliance checks and that regulated local ads protect consumers from seeking potentially harmful information on unregulated international websites.
Join the Conversation
What are your thoughts on pharmaceutical advertising regulations? Share your perspective in the comments below or subscribe to our newsletter for ongoing health policy updates.
Keep reading